Treatment of Anthrax When Sepsis or Extensive Oedema Complicates Cutaneous Disease
Clinical Scenario
Sepsis
This protocol applies to cutaneous anthrax that has progressed beyond a localised presentation to include systemic illness, sepsis, and/or extensive oedema — a presentation classified as severe cutaneous anthrax. The simultaneous presence of systemic compromise significantly alters the management approach compared with uncomplicated cutaneous disease.
Treatment Approach
Management involves empiric combination antibiotic therapy using two agents selected according to local susceptibility patterns. The choice of the first agent depends on whether penicillin susceptibility of the infecting strain is known. The full selection criteria, agent pairing, and duration framework are detailed in the complete protocol.
Treatment Goals
The primary clinical targets are cessation of symptoms and normalisation of body temperature. Once these are achieved, the protocol specifies conditions under which the regimen may be modified.
References
- Systemic anthrax is defined as any of the following: 1) Cutaneous anthrax with systemic illness, sepsis and/or extensive oedema (hereafter referred to as severe cutaneous anthrax).
- In the presence of any of these scenarios, empiric combination therapy with two antibiotics is recommended.
- The first agent should be selected from ciprofloxacin, ampicillin, or penicillin G, based on local penicillin susceptibility patterns (Table 4).
- The second agent should be chosen according to the clinical presentation: intravenous clindamycin for inhalation or injection-related anthrax, oral clindamycin for severe cutaneous anthrax, or intravenous gentamicin for gastrointestinal anthrax.
- Overall, treatment duration should be extended for at least 14 days or until the patient is clinically stable, whichever is longer.
- For severe cutaneous anthrax, when symptoms cease and temperature normalizes, monotherapy can be considered.
View source ↗